-
Diagnostics World | Researchers in California have shown that breast cancer patients with RNA expression levels of ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) in the bottom 50th percentile can confidently be treated with Keytruda (pembrolizumab) as well as surgery. Their cancer would have a zero percent chance of metastasizing in seven years.
Feb 13, 2024
-
Diagnostics World | If artificial intelligence (AI) is to be as insightful as possible in advancing human health, it is not enough to have a patchwork of out-of-context data from which to draw conclusions. That is unfortunately the current situation and at the cost of lost opportunities to better treat patients, identify early biomarkers of disease, and recognize the right endpoints in clinical trials—not to mention eradicating existing biases against marginalized groups of people.
Feb 8, 2024
-
Diagnostics World | Scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health have created a next-generation sequencing (NGS) technology that employs oligonucleotides (oligos)—short single strands of synthetic DNA—as bait for relevant targets of detection.
Feb 7, 2024
-
Diagnostics World | Stanford Medicine investigators are leading the development of a test measuring organ-specific proteins in the blood as a simple and sensible way to estimate biological age. Among the potential applications are screening people for conditions such as heart failure and Alzheimer’s disease, personalizing the intervention they’re prescribed, and signaling sooner the efficacy of investigational drugs based on how well they rejuvenate certain organs.
Feb 6, 2024
-
Diagnostics World | Oxford Nanopore Technologies and Guy’s and St Thomas’ NHS Foundation Trust have collaborated and successfully completed a pilot program meant to deliver a respiratory metagenomics service with an integrated respiratory infection and biosecurity application; Imagine Pharma announced the formation of The Imagine Pharma Foundation, a private, not-for-profit charitable organization dedicated to advancing metabolic research to significantly impact the lives of those affected by diabetes, with a particular emphasis on serving veterans; DNAnexus and TMA Precision Health announced a collaboration to advance basic and translational research for patients who have a rare disease; more.
Jan 31, 2024
-
Diagnostics World | Cleveland Diagnostics intends to accelerate the company’s commercial and corporate development goals; Motif Neurotech has secured funding for the development of lead product, DOT microstimulator, to treat depression; Newcastle University, University of Edinburgh, and Boehringer Ingelheim will begin the most extensive clinical study into liver cirrhosis ever to better understand NASH cirrhosis and identifying translational biomarkers; more.
Jan 30, 2024